The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at least one prior therapy. This combination showed significant improvements in progression-free survival (up to 81%) and overall survival (up to 89%) after 24 months in a Phase III study. If approved, it would be the only bispecific antibody therapy targeting GPRC5D available from the second line of treatment, offering a novel targeted approach that spares healthy immune cells. This recommendation marks a step forward in earlier use of TALVEY in treatment, potentially improving patient outcomes in this complex blood cancer.
Johnson & Johnson (JNJ) shares trade at USD 262.85 on Pluang as of Oct 24, 2026 01:11 WIB, down 1.78% for the day. The stock's market cap stands at $644.22 billion with a dividend yield of 2%. Despite recent news on TALVEY's potential approval, Pluang order activity shows 78% selling and 22% buying interest.
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Procter & Gamble's stock surged 6% following a quarterly earnings beat with core EPS of $2 and net sales of $23.28 billion, surpassing expectations. The company’s price increases are holding up well, driven by resilient higher-income consumers, thoug...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
